Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyOscar Health immune cell function assay Coverage |…
    Ask Trek AI about this page
    CurrentOscar HealthPolicy N/A

    Immune Cell Function Assay

    Customize your policy alerts

    Sign up for all Oscar Health policy alerts

    Know when Oscar Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Oscar Health's coverage stance and clinical background for immune cell function assays (e.g., ImmuKnow, Pleximmune, iQue) and describes indications, limitations, and supporting evidence relevant to diagnosis and management primarily in transplant and primary immunodeficiency contexts.

    Policy Summary
    PayerOscar Health
    PolicyImmune Cell Function Assay
    Policy CodePolicy N/A
    Change TypeAdministrative — no material clinical changes
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionDo not authorize or bill for immune cell function assays; these tests are stated as not meeting coverage criteria and may be denied.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1Not-covered statement
    3Proprietary assays listed
    Class IIIISHLT recommendation
    2Codes referenced

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Not Medically Necessary / Not Covered

    Not covered

    Immune cell function assays: For all situations, an immune cell function assay (e.g., Pleximmune™, Pleximark™) DOES NOT MEET CRITERIA.

    Explicit blanket non-coverage statement in Indications and/or Limitations of Coverage.

    The policy states that immune cell function assays do not meet coverage criteria because there is insufficient published scientific literature demonstrating that these tests are required and beneficial for diagnosis or treatment. Specifically, for all situations an immune cell function assay (for example, Pleximmune™ or Pleximark™) DOES NOT MEET CRITERIA due to lack of evidence of clinical benefit.

    The European Society for Immunodeficiencies (ESID) guideline (2024) recommends a stepwise diagnostic approach for congenital athymia beginning with TREC screening and flow cytometric T-cell enumeration and naive-subset analysis. ESID states that qualitative T-lymphocyte (immune function) tests are of limited value and are not routinely necessary, noting these assays can be unreliable in lymphopenic patients.

    Oscar Health expressly considers immune cell function assays, including proprietary platforms, to be not medically necessary across indications. The policy explicitly states that an immune cell function assay (e.g., Pleximmune™, Pleximark™) DOES NOT MEET CRITERIA for all situations and therefore is not supported for coverage.

    The International Society for Heart and Lung Transplantation (ISHLT) issued a Class III recommendation that the use of the ImmuKnow immune cell function assay "cannot be recommended in adult and pediatric heart transplant recipients for rejection monitoring," with a B level of evidence.

    Coding and Test Interpretation

    Proprietary and general CPT/HCPCS codesCPT
    0018MTransplantation medicine (allograft rejection, pediatric liver and small bowel), measurement of donor and third-party-induced CD154+T-cytotoxic memory cells, algorithm reported as a rejection risk score; Proprietary test: Pleximmune™
    86352Cellular function assay involving stimulation (eg, mitogen or antigen) and detection of biomarker (eg, ATP)
    Additional proprietary codeCPT
    0018MTransplantation medicine (allograft rejection, renal), measurement of donor and third-party-induced CD154+T-cytotoxic memory cells, algorithm reported as a rejection risk score; Proprietary test: Pleximark™
    ImmuKnow response categories
    Strong response≥ 525 ng/ml ATP
    Moderate response226–524 ng/ml ATP
    Low response≤ 225 ng/ml ATP
    ImmuKnow proposed target and illustrative risk values
    Proposed immunologic targetApproximately 280 ng/ml ATP (intersection of risk curves cited by Kowalski et al.)
    Infection risk example25 ng/ml ATP associated with ~12× greater likelihood of infection versus stronger responses
    Rejection risk example700 ng/ml ATP associated with ~30× greater likelihood of cellular rejection versus lower responses

    Provider Actions and Billing Guidance

    Prior Authorization

    Authorization and medical necessity requirement

    Services must meet authorization and medical necessity guidelines; immune cell function assays are explicitly stated as not meeting criteria for any situation and authorization is not supported for these tests.

    • Explicit policy: “For all situations, an immune cell function assay (e.g., Pleximmune™, Pleximark™) DOES NOT MEET CRITERIA.”
    Prior Authorization

    Prior authorization may be required for listed procedure codes

    Claims for listed procedure codes (e.g., 0018M, 86352) may require prior authorization per payer rules and must also comply with any applicable government coverage determinations.

    • Codes referenced in this policy include 0018M and 86352 and may be subject to prior authorization.
    • When government (LCD/NCD or state Medicaid) coverage applies, those policies must be followed.
    Note

    Include test name and performing laboratory on orders/claims

    When ordering or requesting testing, include the specific test name and laboratory performing the assay on the order and claim to ensure accurate processing and review.

    • Policy notes that many labs have developed LDTs and that proprietary tests (e.g., ImmuKnow, Pleximmune) have specific regulatory/status distinctions.
    • Use the procedure codes listed in the policy when billing proprietary assays (see CPT/HCPCS section).
    Step Therapy

    Follow recommended stepwise diagnostic testing before advanced functional assays

    Follow guideline-recommended diagnostic sequencing for suspected primary immunodeficiency: begin with immunoglobulin measurement and flow cytometry (T-cell enumeration and naive subset analysis), reserving in vitro proliferative or other advanced functional tests only if abnormalities on initial screening indicate the need.

    • AAAAI/ACAAI: measure serum immunoglobulins and use lymphocyte proliferation and flow cytometry as indicated; flow cytometry is the screening test to enumerate CD4/CD8 and NK cells.
    • ESID: diagnostic approach begins with TREC screening then flow-cytometric enumeration; qualitative immune function assays are of limited value and unreliable in lymphopenic patients.
    Documentation Required

    Documentation and industry-standard coding required

    Submit accurate clinical documentation of services performed and code claims according to industry-standard coding guidelines; failure to follow coding/billing guidelines may result in claim denial or recoupment.

    • Policy requires coding consistent with CPT, HCPCS, ICD-10, UB, CMS NCCI, and other standard coding resources.
    • Providers are responsible for documentation of services performed for review and reimbursement.
    Billing Rule

    Include test name/lab and use the policy-listed procedure codes on claims

    Identify the specific test (proprietary name when applicable) and include the listed procedure code(s) on the claim: e.g., use 0018M for Pleximark/Pleximmune variants and 86352 for cellular function assays involving stimulation and ATP or similar biomarkers.

    • Policy lists 0018M for Pleximark/Pleximmune proprietary assays and 86352 for cellular function assays.
    • When ordering proprietary assays, indicate the test name and laboratory to align with billing codes.
    Denial Risk

    Denial risk for immune cell function assays (ICFAs)

    Tests identified as immune cell function assays (examples: Pleximmune™, Pleximark™, ImmuKnow®, iQue®) do not meet coverage criteria and may trigger claim denial or prepayment review if submitted.

    • Policy statement: immune cell function assays “DOES NOT MEET CRITERIA” for all situations.
    • Proprietary assays are listed in the CPT/HCPCS section, and submission of these codes may prompt denial consistent with the non-coverage stance.
    Note

    Applicable government coverage determinations govern when in conflict

    If a relevant government policy (LCD/NCD or state Medicaid) conflicts with this policy, the government policy governs the coverage determination and must be followed; failure to follow applicable government coverage may result in denial.

    • The policy disclaimer states government policies supersede this policy when there is a conflict and provides CMS links for current Medicare/Medicaid coverage.

    Background

    Immune cell function assays measure peripheral blood lymphocyte responses to stimulation as a surrogate of cell-mediated immunity. Common measurable outputs include intracellular adenosine triphosphate (ATP) levels and lymphocyte proliferation after mitogen or antigen stimulation; some proprietary assays report algorithm-derived rejection risk scores based on stimulated T-cell markers. These tests have been evaluated in settings such as primary immunodeficiency workup and solid-organ transplant monitoring, but the evidence shows variable performance and has not established consistent clinical utility.

    Definitions

    Immune cell function assay (ICFA) — definition
    DefinitionImmune cell function assay (ICFA): tests measuring peripheral blood lymphocyte response (eg, intracellular ATP levels or proliferation) following stimulation to assess cell-mediated immune function.
    Specimen/sourcePeripheral blood lymphocytes
    Measured outputsIntracellular ATP or lymphocyte proliferation after stimulation
    ATP (Adenosine triphosphate)
    AbbreviationATP = Adenosine triphosphate
    Role in assaysMeasured in some ICFAs (eg, ImmuKnow) as a biomarker of CD4 T‑cell activation
    Units reportedng/ml of ATP in ImmuKnow assay results
    ImmuKnow — FDA‑cleared immune cell function assay
    Test name and developerImmuKnow® (Viracor, formerly Cylex)
    Regulatory statusFDA 510(k) clearance in April 2002 for detection of cell-mediated immunity in immunosuppressed patients; subsequent 510(k) modification in 2010
    Assay principleATP-based assay measuring CD4 T‑cell activation (intracellular ATP after stimulation)
    Pleximmune / Pleximark — proprietary assays and regulatory context
    Pleximmune (Plexision) — indicationApproved via FDA Humanitarian Device Exemption (HDE) for predicting risk of transplant rejection within 60 days in pediatric liver and small bowel transplant patients
    Pleximark (Plexision) — indicationProprietary assay for transplantation medicine (renal) measuring donor and third‑party‑induced CD154+ T‑cytotoxic memory cells reported as a rejection risk score
    Regulatory contextPleximmune received HDE (Humanitarian Device Exemption); other proprietary assays may be marketed as LDTs or under varying regulatory pathways
    Policy Summary
    PayerOscar Health
    PolicyImmune Cell Function Assay
    Policy CodePolicy N/A
    Change TypeAdministrative — no material clinical changes
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionDo not authorize or bill for immune cell function assays; these tests are stated as not meeting coverage criteria and may be denied.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Test InterpretationProvider Actions and Billing GuidanceBackgroundDefinitions